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From Invention to Innovation: Toward Developing an
Integrated Innovation Model for Biotech Firms
Shaista E. Khilji, Tomasz Mroczkowski, and Boaz Bernstein
A review of extant literature reveals various theories on innovation, including tech-
nology push, market pull, and an organizational approach. All of these theories have
been criticized for their lack of integration and inapplicability to today’s competitive
environment. An integrated view of innovation has emerged that synthesizes the
variables in previous approaches. However, the application of this view has been
restricted to investigating the innovation processes within the computer and man-
ufacturing industries, whereas the biotechnology industry has been ignored. This is
despite biotech managers’ well-acknowledged thirst for innovation and the ability of
biotech to shape the way we live. The present article contributes to the literature by
applying an integrated approach to the biotech industry, thereby extending under-
standing of innovation management beyond the traditional field of inquiry. An
integrated approach is of particular relevance to biotech companies, given the com-
plexities of managing the industry’s long development cycle and intense collabora-
tive activities. In-depth interviews with eight organizations in Maryland formed the
basis for an investigation into the challenges of managing the innovation process in
biotechnology firms. The findings revealed that biotech entrepreneurs are ill pre-
pared to lead their organizations through several transformations necessary along
the product life cycle because of their fixation on a technology-push approach and
lack of an understanding of integrated innovation. These leaders also lack the com-
mercialization knowledge necessary to push products to markets, resulting in avoid-
able delays and loss of productivity. The existing research has dispelled myths
associated with biotech. Specifically, it suggests biotech entrepreneurs cannot rely
solely on inventions but must invest in a timely application of knowledge to organ-
izational and market forces to take full advantage of the innovation potential
associated with the industry. This article presents a conceptual framework for
applying the integrated innovation model to biotech firms and makes the case for
incorporating market-oriented mechanisms, building and using appropriate organ-
izational capabilities, developing effective collaborations, and creating parallel
interactions as major elements in a general strategy toward the success and
improved efficiency of biotech companies. The limitations of current research are
discussed, and avenues are highlighted for much-needed future research into the
biotech industry.
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Introduction
D
uring the past two decades biotechnology
has emerged as a vital global industry asso-
ciated with a sustained flow of innovations
and tools for dramatically improving human health
and quality of life worldwide (Gans and Stern, 2004).
Until the early 1980s, the prevailing belief was that no
new company could compete with the pharmaceutical
industry giants because of the enormous costs of de-
veloping a research and development (R&D) infra-
structure (Gassmann, Reepmeyer, and Zedwitz, 2004).
Biotech firms not only challenged the traditional phar-
maceutical companies as the discoverers and develop-
ers of new products but also built credibility in novel
areas such as cell biology, molecular genetics, and drug
delivery. Various authors have endorsed the economic
significance of the biotech industry in today’s econo-
my because of its immense potential for growth (Bak-
er, 2003). Despite this optimism, tensions in managing
growth and innovation have gained attention as bio-
tech companies have matured. Recent research by Ac-
centure (2004) and Babson College, shows that almost
50% of pharmaceutical and biotech executives believe
that companies in their sector become less innovative
as they grow. Characteristics unique to the biotech in-
dustry have also led Baker (2003) to express doubt that
these companies can balance the need to grow with the
urgency to innovate, suggesting that biotech faces or-
ganizational challenges as its products move down the
pipeline. This article seeks to identify some of these
key challenges. To set the stage for this discussion,
consideration must be given to the uniqueness of the
industry.
What Makes Biotech Firms Unique?
Biotechnology companies operate amid uncertainty
and rapid change. They face the increasing cost of
R&D, global competition, and a lack of critical mass
that interferes with the benefits of economies of scale.
Researchers (Baker, 2003; Baker, 2004; Fuchs and
Krauss, 2003) have argued that biotech firms are
unique for at least three reasons. First, because they
are strongly science based, more nimble, and less risk
averse than pharmaceutical companies, innovation
within these firms is far more radical than in other
industries (Gans and Stern, 2004; Powell, Koput, and
Smith-Doerr, 1996). Second, biotech companies rep-
resent tacit knowledge. The generation and economic
exploitation of knowledge thus requires intense sci-
ence-based interactions (Fuchs and Krauss, 2003).
Alliances with other biotech firms, university research
centers, and pharmaceutical companies are the norm
in the industry, providing biotech with faster access to
capital and knowledge, enabling companies to react
more quickly and flexibly to new developments, and
offering better protection of intellectual property
rights (Liebeskind et al., 1995). Finally, the timeline
between establishing the company (i.e., initial invest-
ment) and return (i.e., product availability in the mar-
ket) is long. On average, the entire biotech process,
from scientific discovery to commercialization, can
take up to 15 years (MdBio, 2003) (Figure 1). This
reality exposes entrepreneurs to a plethora of critical
and time-sensitive decisions. For example, how can
the company attract capital and collaborations with-
out a tangible product in the early stages of its life
cycle? Once the invention is in hand, who can the
company partner with for manufacturing, design, and
marketing—especially since most small biotech com-
panies do not possess all the necessary competencies
to make their discoveries available to end consumers?
Gassman et al. (2004) cites a report by Reuters that
demonstrated the unfortunate outcome of these deci-
sions for many companies, including a 90% failure
rate among biotech firms. Thus, despite common be-
lief that biotech industry has transformed itself into a
dynamic source of innovation, not all companies share
in the success. Their plight adds urgency to the inves-
tigation of the challenges these companies face.
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The existing literature on biotech lacks sufficient
discussion of specific management challenges facing
individual firms. Similarly, information on technology
and innovation management (TIM) appears to lack
consistent definitions and sometimes confuses indus-
try types. Because the primary objective of this re-
search is to study the management of innovation in
the biotech industry, the authors adopted a grounded-
theory approach. The main research questions includ-
ed the following: (1) How is innovation understood
and applied within biotech firms? (2) What challenges
do biotech firms face as their products move down the
pipeline? (3) How can these challenges be addressed to
take full advantage of the potential discoveries?
Building on the work of previous scholars in the
field of TIM, this research is aimed at a broader un-
derstanding of the innovation process in biotechnol-
ogy firms. A thorough examination of the wide body
of literature on biotech and on TIM has helped iden-
tify gaps and discrepancies in theory and industry ap-
plication, which were used to develop a discussion of
biotech innovation, and to recommend ways to man-
age the innovation process.
Biotech Literature: The Current Innovation Model
Innovation is the mainstay for small biotech firms;
rapid innovation activities allow them to focus on
niche markets (Chin, 2004). Attempts to describe
biotech innovation have viewed it in terms of se-
quential stages of product development over an ex-
pansive and long period (Delois and Beamish, 2004;
Meyer and Howe, 1997). Figure 2 illustrates one
such typical model (MdBio, 2003). It indicates five
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different stages in product development and availa-
bility: basic research, innovation and invention,
early-stage technology development, product devel-
opment, and production and marketing. An impor-
tant feature of the model, when viewed with Figure
1, is first that it outlines various important activities
in its life cycle (e.g., patent, U.S. Federal Drug Ad-
ministration [FDA] approval, clinical trials, product
design, production, and marketing); second, it di-
rectly refers to at least two critical functions—R&D
and funding and financing—and indirectly indicat-
ing a third one, the use of collaborations to keep
companies funded and active in research. By point-
ing out a split between the prediscovery stages (i.e.,
stages 1 and 2) and the postdiscovery stages (i.e.,
stages 3 to 5) in terms of patent and invention and
building a viable business, this model also highlights
the relevance of different functions at each of these
stages. For example, the importance of basic re-
search looms large in the early stages of develop-
ment and diminishes during later stages. During the
prediscovery stages, or stages of invention, most
available funds are dedicated to R&D activities. Ab-
sence of a commercial product at this stage, howev-
er, undermines efforts to attract private investors for
ongoing research and development. The bulk of
such funding in the United States is thus offered
by the government through the National Science
Foundation or National Institutes of Health. Post-
discovery (i.e., stages 4 and 5 in Figure 2), when a
tangible commercial product becomes available, the
chances of securing financing from venture capital-
ists, angel investors, and corporate venture funds are
higher. At the same time, biotech firms are under
immense economic pressure during these stages to
exploit their technological knowledge in the market-
place, so they can compensate for the necessary in-
itial investment, first phases of significant losses, and
continuing investments in R&D. Figure 2 illustrates
how business competencies become valuable and
dominate the postdiscovery phases—that is, from the
time an invention becomes available. To develop a vi-
able business and to generate profits, resources and
activities must then be directed toward commercializ-
ing the new product.
Although the model described here exposes the rel-
evance of important stages, features, and functions of
biotech innovation, it seems to isolate internal activ-
ities and to separate them from external market forc-
es. In fact, biotech companies rely heavily on external
agencies for competitive advantage (Owen-Smith and
Powell, 2004). A review of the TIM literature here
illustrates the need for a more integrated approach to
studying innovation.
TIM Literature: Toward an Integrated
Innovation Approach
Technology push and market pull, the early inno-
vation models of the 1950s and 1960s, proposed a
unitary progression of phases in the development of
products (similar to what is shown in Figure 2). The
former focused on technology with no concern for
market forces (Lippitt, Watson, and Westly, 1958),
whereas the latter considered the market the primary
source of innovative ideas, assigning R&D a merely
reactive role (Clark, 1979). As the complexities of the
innovation process became apparent, the organiza-
tional approach emerged, revealing innovation as a
continuous process of events and emphasizing the
importance of functionality within the business en-
vironment. Research revolved around identifying
significant structural parameters of organizations,
including concepts of centralization, formalization,
size, and organization goals (Edwards, 2000; Johnson
et al., 2001; Meyer and Mugge, 2001). Conflicting
empirical results led to further confusion, however.
An emerging body of literature in the late 1980s
suggested an integrated approach, reflecting the syn-
thesis of both technology-push and structural param-
eters in the organization. Under this approach, the
innovation process is viewed as the interplay of the
organization’s structural functions toward knowledge
creation. Knowledge—transferred from R&D to man-
ufacturing, marketing, and service through internal
linkages—moves inside and outside the organization
through external linkages. Initiation of the innovation
process thus depends on three main sources: (1) or-
ganizational capabilities; (2) scientific and technolog-
ical developments; and (3) the marketplace. The main
writings to trigger this new body of literature are by
Van de Ven and Rogers (1988) and Pettigrew (1985).
Rothwell’s (1994) integrated view is composed of
interacting and interdependent stages of a complex
network of intra- and extra-organizational linkages,
which connect the firm both internally within
functions and to the broader scientific and technolog-
ical community and the marketplace. This view ap-
pears to be appropriate to the biotech industry because
of its use of tacit knowledge and interdependencies
with the external agencies, which force companies to
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draw on necessary organizational, technological and
scientific, and market resources to innovate.
The present research study was developed with the
integrated approach led by Rothwell (1994), Pettigrew
(1985), and Van de Ven and Rogers (1988) in mind.
As Figures 1 and 2 indicate, the evolution of innova-
tion from an idea to a marketable product in the
biotech industry is multifunctional and involves
intense collaboration. Funding is essential to carry
through various stages of R&D, and the ability to in-
crease development speed is an important factor in
determining a company’s competitiveness. For these
reasons, this study argues that the sequential stage
model presented in biotech literature (Figures 1 and 2)
is inappropriate because it neither highlights the in-
terplay of various functions nor considers the critical
role of the marketplace in the identification of market
niche for innovative products, as has been explained
by the integrated approach.
The literature on TIM has defined innovation in
many ways. For the present article, innovation refers to
a new idea or concept generated by R&D (henceforth
referred to as invention), which is transformed into a
socially usable product. Successful innovation requires
changes in organizational processes and conversion of
an idea into a commercial product that is designed,
manufactured, and adopted by users (Verloop, 2004).
The distinction between invention and innovation is im-
portant because according to the integrated approach,
an invention is converted to successful innovation only
through parallel, directed interactions among organi-
zational, scientific, and market aspects. Invention thus
is one step, and innovation is a whole business process
that creates change from invention, development,
design, and production to marketing.
Research Design and Sample
This exploratory study of innovation in the biotech
industry was conducted in the state of Maryland for
three reasons. First, surveys place Maryland among
the top six regions in the United States (Bond, 2004;
DeVol et al., 2004). Second, Maryland is home to
successful biotech firms, such as MedImmune and
Human Genome, which serve as models to young
biotech firms around the world. Third, Maryland is a
convenient location for interviews because of its prox-
imity to the first two authors.
In-depth, semistructured interviews were used to
collect data. The semistructured format allowed con-
versations to be directed toward the chosen theme of
this study and left respondents free to openly express
their views. In-depth interviews offered the research
team the flexibility to probe and highlight organiza-
tional and other contextual issues that would have re-
mained hidden had a questionnaire survey been used.
Data Collection and Analysis
Interviews were conducted at the macrolevel with
organizations that deal directly with improving the
quality of the business environment for biotech in
Maryland and at the microlevel with specific biotech
firms for an inside perspective on company-specific
issues. Three interviewees ABC, XYZ, and ED, were
contacted for macrolevel interviews. The former two
are nonprofit organizations. ABC in particular offers
a variety of programs (e.g., business development,
manufacturing incentive, workforce development pro-
grams) to advance the commercial development of
bioscience in Maryland. XYZ is a regional coopera-
tive marketing organization to promote the District of
Columbia, Northern Virginia, and suburban Mary-
land as an ideal place for locating or expanding a
business. Industry specialist ED has more than 20
years of experience in the local biotech industry. ED
has founded and managed two small biotech firms
and has knowledge of how biotech industry operates.
These interviews were aimed at including a broader
perspective on the state of biotech firms in the region.
Respondents were asked to share their views on the
role of collaborations for the development of biotech,
the status of biotech firms in this region, economic
policies, incentives, initiatives, the main actors, and
causes of high failure rates among biotech firms.
As this was an exploratory study and the scope was
limited, a total of five companies in different stages of
development—mainly postinvention—were chosen
(Table 1). In line with the aim of the study—to high-
light challenges facing biotech—founders and chief
executive officers (CEOs), who were also scientists in
all cases, were interviewed because they are familiar
with the complexities of managing inside and outside
the laboratory environment. Direct contact was es-
tablished with each CEO via a formal letter or a tel-
ephone call to describe the objective of the study and
to request an appointment with the CEO and the
founder. Interviews of 45 to 75 minutes were con-
ducted during early 2004 by a team of researchers,
including the first two authors.
Interviewers began by asking respondents to ex-
plain what innovation meant to them and to name a
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specific innovation at each of their organizations.
Follow-up questions on these innovations were relat-
ed to networking techniques, funding strategies, reg-
ulatory approvals, and other environment and
organizational factors. This interview technique
caused respondents to narrow their focus to one key
element. Moreover, because this innovation was dis-
cussed in detail, it broadened each respondent’s hori-
zon of thinking to include several dimensions that had
been selected, thus highlighting specific issues and
challenges associated with managing innovation.
Two-person teams conducted the interviews to fa-
cilitate open discussion. All interviews were taped,
and both interviewers took notes. Since the interviews
were semistructured, main categories for the study’s
analysis (e.g., innovation, challenges, collaboration)
were predetermined. Raw data were also tabulated for
an effective analysis (Perreault and Leigh, 1989). To
improve the quality of data and their reliability, two
raters were used (Krippendorff, 1980). The first two
authors read the transcripts several times and tabu-
lated responses independently to develop meaningful
categories such as ‘‘Company GNM defines innova-
tion as’’ and ‘‘Company GNM faces these challeng-
es.’’ Both decided to select quotes from the transcripts
as supporting evidence for each challenge; some of
these quotes are included in the next section of the
article. With two independently developed tables in
hand, discussions were held to evaluate convergence
among raters. The reliability, measured in terms of the
percentage of the authors’ agreement (Perreault and
Leigh, 1989) was found to be 99%. This reliability can
be attributed to clearly predetermined concepts, the
nature of the data, and the motivation and skill of the
judges. Discussions were held further to review raw
and tabulated data in light of the existing literature.
The outcome is presented in the next section.
The sample organizations employed between 13
and 55 employees, with an average of 34. Although
the age of the companies ranged between 3 and 23
years, all but one was established within the last 3 to 6
years. KG was the oldest organization, at 23 years,
and the only firm generating profits. This exception
was welcome because it implied that KG was a mul-
tiproduct company and had gone through the entire
life cycle at least once. KG’s personnel offered expe-
rienced insight into the key issues being discussed. All
other companies had one invention in hand and were
past stage 2 (Figure 2; Table 1). This sample was
therefore suited to understanding organizational chal-
lenges that biotech companies may face after inven-
tion (Accenture, 2004; Baker, 2003).
Results
Interviews from this exploratory study reveal a para-
doxical situation for small biotech companies. In the
following section, each paradox is discussed separately.
Paradox 1: The Harsh Reality—Innovation Is
Worth What the Market Is Willing to Pay
Although innovation is vital for survival in a rapidly
changing business climate and regarded as a critical
differentiator between companies, it is an overused
term that does not necessarily mean the same thing to
everyone (Verloop, 2004). During the initial stage of
the current study, the researchers wondered what in-
novation really means to biotech firms. The inter-
viewers began by asking respondents in the biotech
firms what they understood by innovation. Although
interviewees described innovation as a ‘‘light bulb or
breakthrough’’ moment, they agreed it was not in-
stant but evolved over a period of time. The innova-
tion period was referred to as an exciting time because
it provided companies with a tangible and marketable
product, thereby improving chances of raising capital
to fund late-stage activities, including clinical trials,
Table 1. The Sample Biotech Companies
Company
Code
Total Number
of Employeesa Focus
Age
(Years) Stageb
GNM 15 (9) Research-based 3 Past Stage 2: A recent innovation
AVN 55 Research-based 4 Past Stage 2: A recent innovation
KG 52 Manufacturer and
supplier (Multi-product)
23 Passed through 1–5 at least once:
Established player; holds several patents
VX 36 (31) Research-based 4 Stage 3: Early phase trials
BO 13 (10) Research-based 6 Past Stage 2: A recent innovation
aNumber in parentheses is number of employees in R&D.
b See Figure 2.
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manufacturing, sales, and marketing (Figure 2). It
was considered to be an important stage in the life
cycle of the company but also a nerve-wracking peri-
od because market mechanisms—which often deter-
mined the net value of their invention—were beyond
companies’ control. An interviewee at VX remarked,
‘‘Despite everything, innovation is really worth what
someone is willing to pay for.’’ This reality was a sur-
prise to respondents, who referred to it as a ‘‘rude
awakening’’ and said it added to their stress by ex-
posing them to challenges of a new kind. In the words
of the CEO of GNM, ‘‘We had our major discovery a
few months ago. Now a conundrum we are grappling
with is how to exploit it; how do we publicize and sell
that information?’’
Discovery is indeed the first big step toward pro-
gress. It may also be the first reality check for biotech
management, given their complete reliance on the sci-
entific ability of their teams in the first stages of de-
velopment. As the interviews show, a lack of business
acumen and marketplace knowledge can lead to time
lags that hurt the competitiveness of an innovation.
Paradox 2: Performing a Balancing Act—Forming
Alliances without Revealing Trade Secrets
The respondents in the sample talked about their con-
tinual efforts at establishing collaborations around
the globe. The GNM founder remarked, ‘‘Although
we are a small company, every day—yes, every single
day—we try to form alliances. When I am not on the
phone with the venture capitalist, I am trying to see
who we can potentially collaborate with.’’ Therein lay
a paradox. On one hand, interviewees realized that to
survive in a competitive environment when they
lacked in-house complementary competencies, they
had to seek out collaborations with other companies.
The founder of VX said, ‘‘We are not developing
something that is out there. This is cutting-edge stuff.
You want as much leverage and protection [as you
can get] going forward. But we also realize we don’t
hold all the pieces, so we have to collaborate with
other players out there.’’
On the other hand, biotech is an industry of closely
guarded scientific discoveries and patented informa-
tion. Interviews indicated that forming alliances is not
a straightforward process. During the pre-invention
stage, collaborations are difficult to establish because
of the absence of a tangible product and a high failure
rate among small biotech firms that causes other firms
to adopt a cautious approach. Postdiscovery, biotech
firms face a new challenge as the CEO of GNM ex-
plained. ‘‘When we did not have an innovation, the
dilemma was how to sell just an idea. Now that we do
(have a product)—we are in this netherworld of hav-
ing an incredible discovery that you want to talk
about (for leverage or out of excitement) but can’t
tell all about because its value lies in the secret; and if
you told it you have lost it.’’
Despite a lot of collaborative effort at a certain
level, the very nature of biotech and intellectual prop-
erty legalities requires that trade secrets be protected
up to a certain stage. This paradox makes forming
alliances more difficult than has been mentioned in
the literature. The following discussion outlines other
challenges associated with alliances.
Paradox 3: The Secret of Maintaining Alliances—
Just Because It Doesn’t Work Doesn’t Mean It Is
Dead
The strategic benefits of alliances are alluring, but the
recipe for successful alliance can never be fully written.
Collaboration involves two or more distinct companies
with different goals that quite possibly conflict. Inter-
views revealed companies had to constantly readjust
their expectations and at times live with floundering
alliances. The CEO of VX, which collaborates with a
research institute, pointed out, ‘‘As we mature into con-
ducting trials, we are discovering new differences. They
are academics and we are industry people. We have
timelines, and they don’t understand that. Whenever we
miss a deadline, we have a burn rate of half a million
dollars a month. It kills a small company like us.’’
One would expect floundering alliances to fall apart,
but interviews revealed that biotech may be unique in
this respect. The CEO of AVN explained, ‘‘You know
it is a bad relationship, but continuing to work to-
gether is in everyone’s interest. They are a small com-
pany and we supply a fair amount of their resources.
We need their technology because without it, we would
have to start from scratch and invent something new
ourselves. Neither of us also wants the public exposure
of having to go out there and say the alliance is no
longer existent because that would look bad. So we try
to find ways to make it work.’’ Despite many potential
problems, fruitful collaborations exist. Respondents
believed these were the result of a high level of com-
mitment and mutual trust among all parties.
The interviews reveal that biotech firms engage in
intense collaborative agreements even in the initial
stages of product development. Conflicting interests
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and inexperience at managing collaborations inter-
feres with some companies’ ability to benefit from
these alliances, however.
Paradox 4: Moving Ahead from Invention to
Innovation
As biotech companies proceed through various stages,
they naturally are faced with new realities. All but one
company in the sample were found to be ill equipped
to deal with these challenges. The respondent from
AVN explained, ‘‘How do you prioritize your pro-
jects? How do you evaluate markets and how do you
realize strategic fit? How do you make these decisions?
Really, I don’t have the answers.’’ The interview re-
spondent at ABC reaffirmed this dilemma, citing the
‘‘scientists’ inability to move beyond the initial stage
of innovation’’ as the biggest challenge facing biotech
firms today.
KG, which has multiple products and is the only
well-established and profitable company in the sam-
ple, was atypical. Interviews revealed something else
unique: Over the years, KG had been streamlining
organizational mechanisms, including processes, to
develop a holistic view of projects and products and
to align them with strategic goals and objectives. This
effort improved visibility and control over time and
resources. The CEO at KG commented, ‘‘One thing
we have learned over the years is that how things
happen is most important. I believe organizational
process is crucial. Good companies learn to do things
and let the right processes become ingrained in their
culture.’’
The interviews showed that smaller biotech com-
panies were neither aware of organizational processes
as an integral part of innovation management nor had
developed appropriate capabilities. These companies
were struggling for a suitable course of action after
invention.
Paradox 5: In the Blind Spot—Commercializing
Inventions
Biotech may be based on pure science, but innovation
management is not. The overall success of an inven-
tion requires distinct but complementary strategies
and skills as well as parallel interactions among tech-
nological, market, and organizational knowledge bas-
es (Pettigrew, 1985; Rothwell, 1994; Van de Ven and
Rogers, 1988). Together, these lead to breakthrough
discoveries, provide insights into viable means of serv-
ing the market needs, improve chances of FDA ap-
provals, and ensure a significant financial return.
The interviews indicate that small biotech firms—
frequently formed by scientists around the fruits of
their basic research—are more easily guided to break-
through discoveries because of mastery of scientific
and technological knowledge, which is their core com-
petency. Both organizational and market knowledge
are lacking, however. When it comes to translating
inventions to innovations, firms neither possess the
knowledge to commercialize nor realize the urgency
of grasping market dynamics to speed up the process.
The respondent at ABC remarked, ‘‘There is a differ-
ence between developing a product and developing a
business. Once you get past a certain point you need
people who know how to develop a product and find a
market, build infrastructure, and attract investment.
Not a lot of biotech firms realize that.’’
The dichotomy between commercialization and
R&D activities becomes more pronounced during lat-
er stages of product development, when the need to
understand the marketplace is far more acute. Al-
though biotech managers, a majority of whom are
scientists, hope to drive their ideas to market success,
they often ignore the very basics of transforming their
discoveries into commercially viable products.
Paradox 6: Which Way Forward—Too Much
Control, or Too Little of It?
Regardless of industry type, control must exist, or
there is no organization at all. Another dilemma fac-
ing biotech companies during the postdiscovery stage is
who exercises control and how much of it. This ques-
tion makes good sense in the context in which these
companies operate. First, these companies depend on
venture capitalists and government agencies for funds.
Second, lack of complementary skills pushes compa-
nies to form new alliances that do not necessarily run
smoothly. Founders of biotech firms tend to tighten
their grips in an effort to exercise greater control but
are forced to seek out financing and collaborations for
sustenance, which in essence takes away the control
they want to retain. This situation was described by the
VX founder, as that company was conducting clinical
trials in collaboration with a number of firms at the
time of the interviews. ‘‘I believe control is very im-
portant in this business and I exercise it to keep the
company going. Although right now we have no choice
but to collaborate . . . Going forward, I want to do as
much activity as I can in-house.’’
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From a different perspective, the respondent ED
believed, not giving up control at this stage was a
critical mistake these scientists made. In his words, ‘‘A
smart scientist will step back very early in the process
and let venture capitalists run the company, who have
done it before. Scientists should realize that it is better
to own 10% of a very large company than 100% of
nothing. However, it is a tough lesson. They have
nurtured the company from a very early age, and it is
hard to give up control.’’
Organizational growth is a complex phenomenon
that requires new and effective control mechanisms to
balance the needs for delegation and centralization.
This balance is of particular importance to biotech.
Biotech managers find achieving the right balance dif-
ficult. This critical issue hinders the speed of biotech
development and has created a Red Queen Effect, a
situation in which companies put considerable effort
into expanding their businesses, only to find them-
selves working harder and harder to maintain the sta-
tus quo (Wells, Coady, and Inge, 2003).
Discussion and Implications for Management
How Is Innovation Understood and Applied at
Biotech Firms?
Because biotech firms are known as the source of in-
novation, researchers began by asking respondents
what innovation meant to them and how it was ap-
plied in their organizations. Interviews clearly revealed
a narrow understanding of innovation. Although it
was referred to as the outcome of several years of sci-
entific research, innovation was nonetheless treated as
an isolated event. It was also evident that respondents
were unaware of the distinction between invention (i.e.,
breakthrough scientific discovery) and innovation (i.e.,
a socially usable and marketable product). Previously,
innovation was described as a series of interrelated and
complex activities that ought to be undertaken simul-
taneously; and for every invention to transform into
innovation the effective interplay of three main sources
is important: scientific developments, organizational
capabilities, and the marketplace. An understanding of
the latter two, in particular, appeared to be missing in
the sample. Postinvention, respondents were found to
be grappling with marketplace dynamics and admitted
to being suddenly hit by market realities. Additionally,
firms did not realize the need to simultaneously adapt
organizational mechanisms as inventions moved down
the pipeline. These examples illustrate a fixation on the
technology-push innovation model, described as a tra-
ditional approach in the literature. The interviews also
indicate that since the mainstay of biotech companies is
scientific discovery, or invention, efforts directed at
developing external linkages are weak and haphazard.
A complete focus on scientific developments thus may
prevent companies from pursuing an integrated ap-
proach, which requires an effective synthesis of internal
and external parameters in the organization and suc-
cessful interactions of the aforementioned sources.
What Other Challenges Do Biotech Firms Face as
Products Move down the Pipeline?
The overall importance of alliances suggests that work-
ing jointly is a crucially beneficial mechanism for bio-
tech, which a majority of firms do recognize. Efforts to
establish alliances are fraught with difficulties, how-
ever. Earlier on in the life cycle, due to the confidential
nature of the scientific work, biotech companies may
be unable to spark the interest of prospective partners
in their idea. Interviews also revealed that it would be
incorrect to assume that fully formed collaborations
are fully functional. Alliances do not necessarily bring
in synergistic benefits to both partners. Earning mutual
trust and respect is not easy, given the differing, some-
times incompatible, goals of the partners involved.
Fear of earning bad publicity deters companies from
breaking up alliances, however.
Scientists-turned-entrepreneurs also lack commer-
cialization knowledge, and are ill prepared to convert
invention into innovation, resulting in avoidable de-
lays. The desire to retain control in moving products
down the pipeline, despite the lack of well-developed
in-house complementary skills, also seems to further
hold back the advancement of biotech products.
Statements, such as ‘‘Control is very important’’ and
the notion that that if you want something done right,
you have got to do it yourself are indicative of this
desire (see Paradox 6).
The current study, in its search of key challenges
facing biotech, has also been able to bring some
industry-specific realities to the forefront, identifying
and dispelling myths. First, although cooperation
may be the norm in biotech and the number of alli-
ances may be growing exponentially, forming and
maintaining these alliances is not easy, nor are these
alliances necessarily fruitful. Recent research by Ac-
centure (2004) indicates that despite increasing atten-
tion, executives in pharmaceutical companies of all
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sizes are also not getting the benefits from alliances
that they seek. The growth in the number of alliances
therefore must be interpreted with caution. Second,
biotech is generally believed to be an exciting industry
with immense innovation capabilities. Wrong again—
not all biotech companies have necessarily incorpo-
rated a holistic understanding of innovation that goes
hand in hand with managing the innovation process
effectively in an integrated manner and developing
new products speedily. This may be the primary rea-
son why so many promising inventions in research
laboratories fail to see the light of the day. Most sig-
nificantly, the rosy picture eloquently presented in the
literature does not depict real challenges faced by
small biotech firms. Researchers need to look beyond
impressive overall industry facts to explore critical is-
sues. The recent biotech revolution may have great
potential, but it is still in its early growth phase. Oliver
(2003) argued that sorting out the winners is just as
tough as in the modern industrial or information ages,
when hundreds of railroads, car companies, and soft-
ware firms competed with one another. Few survived.
The research described in this article shows that bio-
tech cannot rely solely on invention but must invest in
a timely application of knowledge to organizational
and market forces. Dedicated leaders with vision,
commitment, strong management teams, and effec-
tive business plans will determine the winners.
An Integrated Biotech Innovation Model
A synthesis of the critical issues highlighted in this
article has resulted in a proposal for an innovation
model that is appropriate for biotech firms. This mod-
el depicts the complex network of intraorganizational
and interorganizational linkage and consists of paral-
lel, interacting, and interdependent stages that sup-
port an integrated approach to managing innovation
(Rothwell, 1994). Unlike the traditional technology-
push model that the sample companies mostly pursue,
this innovation model is developed with a view to
providing direction to biotech firms in understanding
how to move products and inventions along the pipe-
line efficiently to address organizational and manage-
ment challenges.
How Can These Management Challenges Be
Addressed?
Previously in this article it was suggested that the do-
main of biotech activities be divided into three main
categories: funding and financing, R&D, and estab-
lishing and maintaining alliances whose nature will
vary on the basis of a distinction between pre-inven-
tion (i.e., discovery) and postinvention stages. In ad-
dition, the discussion of Figures 1 and 2 has also
highlighted important activities in the biotech prod-
ucts life cycle: patent acquisition, FDA and regulatory
approvals, clinical trials, product design, production,
and marketing. The model incorporates all of these
activities, which will be expected to serve as the back-
drop to three sources outlined in the integrated
approach: marketplace dynamics, organizational ca-
pabilities, and scientific and technological knowledge.
Together these will determine the direction of building
several necessary in-house organizational competen-
cies. For example, prior to invention, although activ-
ities may be focused on scientific aspects companies
will also need to adopt a proactive approach toward
understanding market dynamics, sustaining existing
organizational capabilities, and building new skills
and capabilities—both organizational and commer-
cial—for use in the future. Incorporating a strong
market orientation will also broaden scientists’ un-
derstanding of innovation to help them deal with so-
called harsh market realities. With an invention in
hand, the emphasis shifts to adapting structures to
new organizational capabilities, developing still newer
capabilities for further growth, and sustaining flexible
organizational structures that are open to modifica-
tions. In particular, commercialization activities need
to be effectively used because the main issue is how to
successfully sell the innovation. The business benefits
need to be clearly communicated early on; parallel
development of an effective collaborative interface
between R&D and marketing can be useful. These
activities will help transform an invention into an in-
novation that can satisfy the market and generate
revenues and profits. At this stage, knowledge of the
regulatory approval process is also required to obtain
a patent. As suggested previously, involving market-
ing managers and legal experts, as well as training
scientists in business development, will ensure a
smoother transition between these distinct and inter-
acting stages.
For establishing collaborations, the postinvention
period may be easier but also exposes companies to
intellectual property issues. Building and maintaining
effective alliances remains a significant challenge.
With integrated innovation management running
through the entire life cycle, the process will result
in a viable business if the innovation can proceed
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smoothly through clinical tests, product designs, pro-
duction, and marketing and if it can satisfy market
needs. Biotech companies should identify common
goals earlier and should use formalized contracts with
clear-cut roles and expectations to avoid conflicts with
their alliance partners. These companies should also
learn to place themselves in a better strategic position
with respect to gaining valuable collaborations. Gans
and Stern (2004) propose an idea factory whereby
small biotech firms can play established companies
against each other to auction the invention and inno-
vation to the highest bidder. This strategy requires
market research and product profiling (Garnsey,
2003). Companies also need to weigh the pros and
cons of alliances and learn to relinquish control when-
ever necessary to fully use complementary assets of-
fered by external agencies. Chesbrough (2003) argues
that this approach can lead biotech companies to de-
veloping and implementing effective innovation man-
agement strategies.
The proposed model departs from the linear and
sequential models apparently used by the biotech in-
dustry. As interviews indicated, these models have
made companies more vulnerable to inflexible organ-
izational mechanisms and a general lack of under-
standing of the intense impact of marketplace forces,
leading to poor decisions. If biotech managers under-
stand the interplay of external and internal mecha-
nisms—and specifically the interactivity of science
and technology, organizational capabilities, and mar-
ketplace dynamics in decision making—they are likely
to be in better strategic positions for long-term eco-
nomic survival.
Limitations and Directions for
Future Research
Several questions that need further research emerged
during this exploratory study. First, the proposed
model demonstrated a complex interaction of activi-
ties influenced by three main sources, namely scientific
development, organization capabilities, and the mar-
ketplace (Figure 3). This article does not allow for a
more detailed investigation of these sources. Further
research may therefore investigate these sources by
means of case studies of firms. Each of these sources
would require application of methods, models, and
theories to better integrate its impact on the innova-
tion process in biotechnology firms. Second, although
the proposed model establishes interactive associa-
tions between various activities, the present study has
not found evidence in sample companies to support
these interactions. In addition, it focuses only on
R&D, financing, and alliances as the mainstays of
the biotech product development process and under-
emphasizes the significance of legal aspects, produc-
tion, and clinical testing. Further research is needed to
refine and broaden the scope of the model for a more
comprehensive understanding of how companies use
their innovation process to gain successful outcomes.
Third, the cross-sectional nature of the study hinders
its ability to establish causality between constructs
and variables. A further complication is the evolution
of firms in their business environment over time. For
example, biotechnology firms are constantly exposed
to new scientific developments that may impact their
research and development efforts. In other words,
they would often need to align their internal capabil-
ities with the new technological challenges. Firms
would therefore be faced with new challenges at dif-
ferent points of time and would need to apply differ-
ent management efforts across the stages of the
innovation process. This calls for a more dynamic
and longitudinal view of the innovation process, tak-
ing into account a more complex set of both internal
factors as well as external factors across time, to ex-
plore the relationships introduced in this study and
enhance their ability to explain both the innovation
successes and failures. Fourth, although biotech is
unique among industries, further studies are needed to
explore the integrated innovation mechanisms in oth-
er industries for cross-comparisons leading to a more
complete view of antecedents of innovation across
industries.
The model for biotech innovation management
needs further verification and development through
research in additional organizations, but even as it
stands, it can serve as a useful roadmap for posing
crucial research questions. The most important is this:
How do organizational capabilities—understood not
just as knowledge and skills systems but also as sys-
tems of management and control—change as busi-
nesses move from invention to innovation? This broad
question can be further disaggregated into more
detailed questions spanning the whole spectrum of
leadership, organizational flexibility, and knowledge
management within firms.
The biotech industry provides an important con-
text for developing broad theories of innovation, since
it is so uniquely dependent on it. Like the industry it
seeks to study, biotech research is in an immature
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stage. Each of these paradoxes developed in this ar-
ticle offers fascinating avenues for much-needed fur-
ther studies. What are the implications of an overly
narrow understanding of innovation—as pure discov-
ery—by biotech entrepreneurs? What are the most
significant errors biotech managers commit while
dealing with products under development? How best
to manage the constantly changing alliances that bio-
tech need to nourish to survive? How best to make the
transition from scientific invention to commercial suc-
cess? When to tighten and when to loosen control to
maintain creativity but also to eliminate projects that
lack promise and respond to inevitable commerciali-
zation? Future research directed toward exploring
these questions can lead to a better understanding of
this innovative yet underresearched industry.
Conclusions
This article has highlighted the challenges small bio-
tech companies face in their search for marketable
science and has suggested ways to overcome these
challenges. By shedding light on the realities of the
biotech industry, several myths associated with the
industry have been dispelled. On the basis of the re-
search described in this article, and on existing models
for the integrated innovation approach, a new model
of innovation is proposed that would be appropriate
for biotech companies (Figure 3). Biotech managers
are advised to use this model to guide them toward
more effective decisions.
The research for this article revealed that informa-
tion relating to organizational and managerial issues in
The dotted line presents the distinction between pre-invention and postinvention stages.
Regulatory approvals are required both before and after clinical trials to grant or withdraw approved drug status. 
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the biotech industry is scant and mostly focused on
Europe, California, or Massachusetts. Maryland has
been neglected in the literature, despite its prominence
on the world stage. The current study contributes to
filling this gap in the literature. The authors intend to
build on this research, and it is hoped that these find-
ings will intrigue other researchers to explore this topic,
in terms of the industry as well as the geographic area.
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